Logo
 
USD 921.84  CAD 1208.93  EUR 863.80  AUD 1224.56  GBP 734.23 
 

Browse Categories

Search Options

Search terms:

Listing type:

All  Fixed Price  Auction

Product type:

All  Digital  Physical

Price range:

USD  to USD

Origin country:

Ships to:

Order by:

Active vendor:

Automatic fulfillment:

Multisig options:

Bulk discounts:

In stock:

Payment type:

Cryptocurrency:

Average vendor processing:

Vendor trust level:

to

Exchange Rates

Bitcoin (BTC)

United States Dollar (USD)
921.84
 
Canadian Dollar (CAD)
1,208.93
 
Euro (EUR)
863.80
 
Australian Dollar (AUD)
1,224.56
 
British Pound (GBP)
734.23
 
Deposits & Withdrawals
 

Monero (XMR)

United States Dollar (USD)
11.63
 
Canadian Dollar (CAD)
15.26
 
Euro (EUR)
10.90
 
Australian Dollar (AUD)
15.46
 
British Pound (GBP)
9.27
 
Deposits & Withdrawals
 

The above rates are updated every 10 minutes and taken using a weighted average of major exchange platforms.

 

DILAUDID 2mg $10 X 30 Pills HYDROMORPHONE

DILAUDID 2mg AKA HYDROMORPHONE. These are instant release straight from pharmacy bottle. #1 TRUSTED VENDOR FOR USA PHARMACEUTICAL GRADE PILLS PRICE: $10 QTY: 30 PILLS Dilaudid Tablets The usual starting dose for DILAUDID tablets is 2 mg to 4 mg, orally, every 4 to 6 hours. Appropriate use of the DILAUDID TABLETS must be decided by careful evaluation of each clinical situation. A gra...

Sold by TEAMTEXAS - 56 sold since May 25, 2016  Vendor Level 9 Trust Level 8

 
Features
 
Product class
Physical package
 
Quantity left
2 items
 
Ends in
Never
 
 
Features
 
Origin country
United States
 
Ships to
United States
 
Payment
FE Listing 100%
 
 

Purchase price: USD 300.00

Qty:  
0.3254 BTC / 25.7954 XMR

 

Product Description

DILAUDID 2mg AKA HYDROMORPHONE. These are instant release straight from pharmacy bottle. #1 TRUSTED VENDOR FOR USA PHARMACEUTICAL GRADE PILLS

PRICE: $10
QTY: 30 PILLS

Dilaudid Tablets

The usual starting dose for DILAUDID tablets is 2 mg to 4 mg, orally, every 4 to 6 hours. Appropriate use of the DILAUDID TABLETS must be decided by careful evaluation of each clinical situation.

A gradual increase in dose may be required if analgesia is inadequate, as tolerance develops, or if pain severity increases. The first sign of tolerance is usually a reduced duration of effect. Patients with hepatic and renal impairment should be started on a lower starting dose (See CLINICAL PHARMACOLOGY - Pharmacokinetics and Metabolism).
Individualization Of Dosage

The dosage of opioid analgesics like hydromorphone hydrochloride should be individualized for any given patient, since adverse events can occur at doses that may not provide complete freedom from pain.

Safe and effective administration of opioid analgesics to patients with acute or chronic pain depends upon a comprehensive assessment of the patient. The nature of the pain (severity, frequency, etiology, and pathophysiology) as well as the concurrent medical status of the patient will affect selection of the starting dosage.

In non-opioid-tolerant patients, therapy with hydromorphone is typically initiated at an oral dose of 2-4 mg every four hours, but elderly patients may require lower doses (see PRECAUTIONS -Geriatric Use).

In patients receiving opioids, both the dose and duration of analgesia will vary substantially depending on the patient's opioid tolerance. The dose should be selected and adjusted so that at least 3-4 hours of pain relief may be achieved. In patients taking opioid analgesics, the starting dose of DILAUDID should be based on prior opioid usage. This should be done by converting the total daily usage of the previous opioid to an equivalent total daily dosage of oral DILAUDID using an equianalgesic table (see below). For opioids not in the table, first estimate the equivalent total daily usage of oral morphine, then use the table to find the equivalent total daily dosage of DILAUDID.

Once the total daily dosage of DILAUDID has been estimated, it should be divided into the desired number of doses. Since there is individual variation in response to different opioid drugs, only ½ to 2/3 of the estimated dose of DILAUDID calculated from equivalence tables should be given for the first few doses, then increased as needed according to the patient's response.

Since the pharmacokinetics of hydromorphone are affected in hepatic and renal impairment with a consequent increase in exposure, patients with hepatic and renal impairment should be started on a lower starting dose (See CLINICAL PHARMACOLOGY - Pharmacokinetics and Metabolism).

In chronic pain, doses should be administered around-the-clock. A supplemental dose of 5-15% of the total daily usage may be administered every two hours on an “as-needed” basis.

Periodic reassessment after the initial dosing is always required. If pain management is not satisfactory and in the absence of significant opioid-induced adverse events, the hydromorphone dose may be increased gradually. If excessive opioid side effects are observed early in the dosing interval, the hydromorphone dose should be reduced. If this results in breakthrough pain at the end of the dosing interval, the dosing interval may need to be shortened. Dose titration should be guided more by the need for analgesia than the absolute dose of opioid employed.

hydromorphone pain killers oxycodone norco dilaudid pain vicodin